SITC | Conference

Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.

A study presented at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting suggested that ipilimumab (Yervoy) plus nivolumab (Opdivo) for patients with metastatic or unresectable angiosarcoma was well-tolerated.

“The data reported, in addition to its ease of use, demonstrate the potential of [tavokinogene telseplasmid] in combination with pembrolizumab as a next-generation intratumoral IL-12 therapy that can induce regression of both locally treated and untreated distant and visceral lesions,” said Paolo A. Ascierto, MD.

Marjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Luca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Mario Sznol, MD, from Yale University, discusses where the field of immune-oncology will be 1 and 5 years from now at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).